<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4402">
  <stage>Registered</stage>
  <submitdate>20/04/2007</submitdate>
  <approvaldate>20/04/2007</approvaldate>
  <nctid>NCT00464308</nctid>
  <trial_identification>
    <studytitle>A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg</studytitle>
    <scientifictitle>The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CR006397</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastro-oesophageal Reflux</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Esomeprazole
Treatment: drugs - Rabeprazole
Treatment: drugs - Esomeprazole

Active Comparator: 001 - Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily

Active Comparator: 002 - Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily

Active Comparator: 003 - Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily


Treatment: drugs: Esomeprazole
20mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily

Treatment: drugs: Rabeprazole
20mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily

Treatment: drugs: Esomeprazole
40mg once daily for 28days - 1 placebo tab/cap &amp; 1 active tab/cap daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The Number of Patients With Complete Resolution of Heartburn by Week 4 - Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.</outcome>
      <timepoint>week 4 of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4 - Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4 - Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4 - Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The Median Time to Complete Resolution of Heartburn Symptoms.</outcome>
      <timepoint>week 4 of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Median Time to Complete Relief of Regurgitation Symptoms</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Heartburn (defined as a feeling of burning or pain, rising from the epigastrium or
             lower part of the chest up towards the neck) with or without regurgitation

          -  Patients must have had episodes of heartburn with or without regurgitation for 3
             months or longer, and for &gt;= 3 days in the 7 days prior to randomisation

          -  Able to understand and complete questionnaires, able to give written informed consent,
             and have access to a telephone</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients requiring endoscopy within 4 weeks of randomisation or with gastrointestinal
             symptoms that, in the opinion of the investigator, require further investigation prior
             to or coincident with initiation of PPI therapy which would include, but are not
             limited to, alarm symptoms such as unintentional weight loss, progressive difficulty
             swallowing (dysphagia), iron deficiency anaemia and epigastric mass

          -  Significant gastrointestinal obstruction, major gastric or oesophageal surgery
             (excluding appendectomy or cholecystectomy), oesophageal stricture or pyloric
             stenosis, extra-oesophageal manifestations of reflux disease

          -  Patients with Barrett's oesophagus (&gt;3cm), Zollinger-Ellison Syndrome, scleroderma,
             malignancy (other than non-melanoma skin cancers) present within the last 5 years,
             hypersensitivity to rabeprazole or esomeprazole or any PPI, or any other significant
             condition that, in the opinion of the investigator, could interfere with the patients
             participation or compliance in the study such as past or current history of alcohol or
             drug abuse, hepatic, renal, pulmonary, respiratory abnormalities, or who have
             participated in an investigational drug or investigational device study within 30 days
             prior to the baseline visit or who are expected to do so during the 4 week study
             period

          -  Female patients who are currently pregnant or breast feeding, or who, in the opinion
             of the investigator, may become pregnant throughout the study

          -  Use of histamine-2 receptor antagonists (H2RAs) within 7 days of randomisation,
             anticholinergics, cholinergics, spasmolytics, opiates, sucralfate, proton pump
             inhibitors (PPIs), prokinetics, antibiotics (in relation to H. pylori treatment) or
             bismuth compounds within 14 days of randomisation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1392</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Belconnen</hospital>
    <hospital> - Bondi Junction</hospital>
    <hospital> - Brookvale</hospital>
    <hospital> - Browns Plains</hospital>
    <hospital> - Campbelltown</hospital>
    <hospital> - Campsie</hospital>
    <hospital> - Caringbah</hospital>
    <hospital> - Castle Hill</hospital>
    <hospital> - Charlestown</hospital>
    <hospital> - Dapto</hospital>
    <hospital> - Darlinghurst</hospital>
    <hospital> - Dubbo</hospital>
    <hospital> - Elizabeth</hospital>
    <hospital> - Fairfield</hospital>
    <hospital> - Hoppers Crossing</hospital>
    <hospital> - Ingleburn</hospital>
    <hospital> - Leichhardt</hospital>
    <hospital> - Maroubra</hospital>
    <hospital> - Melton</hospital>
    <hospital> - Mount Druitt</hospital>
    <hospital> - Oaklands Park</hospital>
    <hospital> - Royal Park</hospital>
    <hospital> - Sydney</hospital>
    <hospital> - Wentworthville</hospital>
    <hospital> - Wyoming</hospital>
    <postcode> - Belconnen</postcode>
    <postcode> - Bondi Junction</postcode>
    <postcode> - Brookvale</postcode>
    <postcode> - Browns Plains</postcode>
    <postcode> - Campbelltown</postcode>
    <postcode> - Campsie</postcode>
    <postcode> - Caringbah</postcode>
    <postcode> - Castle Hill</postcode>
    <postcode> - Charlestown</postcode>
    <postcode> - Dapto</postcode>
    <postcode> - Darlinghurst</postcode>
    <postcode> - Dubbo</postcode>
    <postcode> - Elizabeth</postcode>
    <postcode> - Fairfield</postcode>
    <postcode> - Hoppers Crossing</postcode>
    <postcode> - Ingleburn</postcode>
    <postcode> - Leichhardt</postcode>
    <postcode> - Maroubra</postcode>
    <postcode> - Melton</postcode>
    <postcode> - Mount Druitt</postcode>
    <postcode> - Oaklands Park</postcode>
    <postcode> - Royal Park</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Wentworthville</postcode>
    <postcode> - Wyoming</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen-Cilag Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to compare, the number of patients with heartburn and
      regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole
      20 mg or esomeprazole 40 mg.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00464308</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen-Cilag Pty Ltd Clinical Trial</name>
      <address>Janssen-Cilag Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>